<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00-09:30</td>
<td>Registrations</td>
</tr>
<tr>
<td>09:30-10:00</td>
<td>Opening Ceremony</td>
</tr>
<tr>
<td>10:00-10:45</td>
<td>Keynote Forum</td>
</tr>
<tr>
<td>Introduction</td>
<td>Title: Lower GI bleeding in patients with cirrhosis</td>
</tr>
<tr>
<td></td>
<td>Maxwell Chait, Columbia University, USA</td>
</tr>
<tr>
<td>10:00-10:45</td>
<td>Title: Acute Pancreatitis Treatment</td>
</tr>
<tr>
<td></td>
<td>Vincenzo Neri, University of Foggia, Italy</td>
</tr>
<tr>
<td>10:45-11:30</td>
<td>Panel Discussion</td>
</tr>
<tr>
<td>11:30-11:45</td>
<td>Networking &amp; Refreshment Break</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>Title: Hepatitis B Infection is now 30 times more common in UK than US children!</td>
</tr>
<tr>
<td></td>
<td>Paul Desmond, Hepatitis B Trust, UK</td>
</tr>
<tr>
<td>11:45-12:15</td>
<td>Title: The Epidemiology of HCV and PWIDs in the United States</td>
</tr>
<tr>
<td></td>
<td>Seth Kuranz, Decision Resources Group, USA</td>
</tr>
<tr>
<td>12:15-12:45</td>
<td>Title: Access time to antiviral c treatment is equal for very fragile drug users and inmates, longer for drug centers patients: interest in having a dedicated multidisciplinary team</td>
</tr>
<tr>
<td></td>
<td>André-Jean REMY, Perpignan Hospital, France</td>
</tr>
<tr>
<td>12:45-13:15</td>
<td>Title: A Virus-like Particle of HBV preS Elicits Robust Immune Responses</td>
</tr>
<tr>
<td></td>
<td>Ming Luo, Georgia State University, USA</td>
</tr>
<tr>
<td>Lunch break</td>
<td>13:45-14:30</td>
</tr>
<tr>
<td>13:45-15:00</td>
<td>Title: Immune persistence after hepatitis B vaccination in infancy: Fact or fancy?</td>
</tr>
<tr>
<td></td>
<td>Terence T Lao, Chinese University of Hong Kong, Hong Kong</td>
</tr>
<tr>
<td>15:00-15:30</td>
<td>Title: Hepatitis C and Sustainable Development Goals 2030</td>
</tr>
<tr>
<td></td>
<td>Ruchika Sharma, Decision Resources Group, India</td>
</tr>
<tr>
<td>15:30-16:00</td>
<td>Title: Clinical trials and pharmacology of Hebernasvac, a newly registered therapeutic vaccine for chronic Hepatitis B: crossroad of biotechnology, adjuvant strategies and Liver Immunology</td>
</tr>
<tr>
<td></td>
<td>Julio Cesar Aguilar Rubido, Center for Genetic Engineering and Biotechnology, Cuba</td>
</tr>
<tr>
<td>Networking &amp; Refreshment Break</td>
<td>16:00-16:15</td>
</tr>
<tr>
<td>16:15-16:45</td>
<td>Title: Advances in Hepatology</td>
</tr>
<tr>
<td></td>
<td>Maxwell Chait, Columbia University, USA</td>
</tr>
<tr>
<td>16:45-17:15</td>
<td>Title: Epidemiology and Disease Burden of Chronic Hepatitis C in Selected Middle Eastern Countries</td>
</tr>
<tr>
<td></td>
<td>Abdulrahman A. Aljumah, King Saud bin Abdulaziz University for Health Sciences, Saudi</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
</tr>
<tr>
<td>--------------</td>
<td>------------------------------------------</td>
</tr>
<tr>
<td>09:30-10:15</td>
<td>Keynote Forum</td>
</tr>
<tr>
<td>10:15-10:45</td>
<td>Pancreatic Cancer</td>
</tr>
<tr>
<td>10:45-11:15</td>
<td>Hepatocellular Carcinoma</td>
</tr>
<tr>
<td>11:15-11:30</td>
<td>Networking &amp; Refreshment Break</td>
</tr>
<tr>
<td>11:30-12:00</td>
<td>Pancreatic Cancer</td>
</tr>
<tr>
<td>12:00-12:30</td>
<td>Hepatocellular Carcinoma</td>
</tr>
<tr>
<td>12:30-13:00</td>
<td>Pancreatic Cancer</td>
</tr>
<tr>
<td>13:00-13:30</td>
<td>Hepatocellular Carcinoma</td>
</tr>
<tr>
<td>14:15-14:45</td>
<td>Poster presentations</td>
</tr>
<tr>
<td>HEP01</td>
<td>Title: AKR7A3 suppresses tumorigenicity and chemoresistance in hepatocellular carcinoma through attenuation of ERK, c-Jun and NF-κB signaling pathways</td>
</tr>
<tr>
<td>HEP02</td>
<td>Title: The impact of IL-6 levels to activate immune system as pro-inflammatory properties in patients with CHB infection</td>
</tr>
<tr>
<td>HEP03</td>
<td>Title: Improvement of patients' understanding and accessibility to healthcare services increase implementation of hepatitis C virus therapy in methadone maintenance treatment patients</td>
</tr>
<tr>
<td>Time</td>
<td>Title</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 14:45-15:15 | **Title:** Discover and quantification of novel fatty liver and fibrosis biomarkers using proteomics  
**Title:** The Global Burden of Hepatitis C in relation to Sustainable Development Goals 2030 targets  
**Title:** Use of differential temperature evaluation as feedback for insulin delivery monitoring in acute severe (life threatening) glucose metabolism disorders | Ruchika Sharma, Decision Resources Group, India  
Vary Coulie, Translational Medicine Laboratory, Belgium  
Seth Kuranz, Decision Resources Group, USA |
| 14:45-15:15 | **Title:** The Global Burden of Hepatitis C: A 10-year Forecast | Yu-Jou Tsai, Yuan’s General Hospital, Taiwan |
| 14:45-15:45 | **Title:** Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer | Qingyong Ma, Xi’an Jiaotong University, China |
| 15:45-16:15 | **Title:** Down-regulation of miR-185 in liver fibrosis correlates with RHEB and RICTOR overexpression and HSCs activation | Jun Cheng, Peking University, China |
| 16:15-16:30 | **Title:** Knowledge, attitude and practice of Sudanese house officers and registrars regarding pancreatic cancer in three hospitals in Khartoum state, Sudan 2016-2017 | Mansour Osman Elhaj, University of Khartoum, Sudan |
| 16:30-17:00 | **Title:** Panel Discussion                                           | Day 3 August 12, 2017  
Networking  
Award Ceremony |